

Nasopharyngitis (Common Cold) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/N24835A04DAEN.html>

Date: January 2020

Pages: 42

Price: US\$ 2,000.00 (Single User License)

ID: N24835A04DAEN

Abstracts

Nasopharyngitis (Common Cold) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngitis (Common Cold) - Pipeline Review, H1 2020, provides an overview of the Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline landscape.

Nasopharyngitis also known as common cold is an infectious, inflammatory condition that affects the throat and nasal passages. The virus can spread through droplets in the air when someone who is sick coughs, sneezes or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngitis (Common Cold) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide also

reviews of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 3, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).

The pipeline guide reviews pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Nasopharyngitis

(Common Cold) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Nasopharyngitis (Common Cold) - Overview

Nasopharyngitis (Common Cold) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Nasopharyngitis (Common Cold) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nasopharyngitis (Common Cold) - Companies Involved in Therapeutics Development

Charleston Laboratories Inc

Firebrick Pharma Pty Ltd

Karo Pharma AB

Orbis Biosciences Inc

Pfizer Inc

Sanotize Research And Development Corp

Tris Pharma Inc

Nasopharyngitis (Common Cold) - Drug Profiles

Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

guaifenesin ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nasopharyngitis (Common Cold) - Dormant Projects

Nasopharyngitis (Common Cold) - Discontinued Products

Nasopharyngitis (Common Cold) - Product Development Milestones

Featured News & Press Releases

Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting

Codeine Antitussive With a Popular Anti-Histamine

Oct 10, 2013: Spriaso completes FDA Meeting on Tuxarin ER

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Nasopharyngitis (Common Cold), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Nasopharyngitis (Common Cold) - Pipeline by Charleston Laboratories Inc, H1 2020
Nasopharyngitis (Common Cold) - Pipeline by Firebrick Pharma Pty Ltd, H1 2020
Nasopharyngitis (Common Cold) - Pipeline by Karo Pharma AB, H1 2020
Nasopharyngitis (Common Cold) - Pipeline by Orbis Biosciences Inc, H1 2020
Nasopharyngitis (Common Cold) - Pipeline by Pfizer Inc, H1 2020
Nasopharyngitis (Common Cold) - Pipeline by Sanotize Research And Development Corp, H1 2020
Nasopharyngitis (Common Cold) - Pipeline by Tris Pharma Inc, H1 2020
Nasopharyngitis (Common Cold) - Dormant Projects, H1 2020
Nasopharyngitis (Common Cold) - Discontinued Products, H1 2020

About

Global Markets Direct's, 'Nasopharyngitis (Common Cold) - Pipeline Review, H1 2014', provides an overview of the Nasopharyngitis therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nasopharyngitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for Nasopharyngitis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

I would like to order

Product name: Nasopharyngitis (Common Cold) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/N24835A04DAEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N24835A04DAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970